Vertex Pharmaceuticals Incorporated - VRTX Net earnings per one share for the last twelve months

Vertex Pharmaceuticals Incorporated (VRTX) - corporate logo

Vertex Pharmaceuticals generates revenue through the exclusive supply of high-cost orphan disease medications via insurance mechanisms. The company's superprofits are based on its monopoly in cystic fibrosis therapy and high operating margins. Supply reliability is guaranteed by strictly controlled cold chains. The annual EPS TTM YoY trend demonstrates profit dynamics, where the current mark equals 9.40.

VRTX: vrtx.com Net earnings per share for the last 12 months 02/11/2024 - 11/17/2026

Vertex Pharmaceuticals - analytical breakdowns and key metrics (VRTX)

- stock quotes and analyst forecast:
Fundamental company valuation:VRTX - Vertex Pharmaceuticals Incorporated
Brand item of Vertex Corp

This indicator serves as a key filter during initial screening and capital resilience stress testing. It measures the rate of change in net earnings per share over a rolling year, reflecting the actual efficiency of value generation. By analyzing the annual percentage growth of EPS TTM, an investor can observe profitability trends without seasonal distortions. For Vertex Pharmaceuticals (VRTX), such a trajectory confirms the strength of organic growth and its monopoly position without the need for aggressive acquisitions.

Competitor analysis

Earnings per one share for the last 12 months ALNY|INSM: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months United Therapeutics Corp. (UTHR)|BMRN (BioMarin) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months BBIO (BridgeBio)|Earnings per share for the last twelve months bgm.ltd (BGM)|COGT (Cogent Biosciences Inc) - Earnings per share for the trailing year|Earnings per share for the last twelve months Xeris Biopharma Holdings XERS|KROS (Keros Pharma) - Earnings per one share for the last 12 months|Arcturus Therapeutics - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ETON (Eton Pharmaceuticals)|KMDA: Net earnings per share (EPS TTM)|Fulcrum Therapeutics Inc (FULC) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months abeonatherapeutics.com|MREO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) PLX|Net earnings per share for the last 12 months Pliant Therapeutics, Inc. PLRX|Net earnings per share (EPS TTM) APLT (Applied Therapeutics Inc.)|Net earnings per share (EPS TTM) Rein Therapeutics Inc. RNTX|gelteq.com - Net earnings per share (EPS TTM)|AYTU - Net earnings per share (EPS TTM)|CMMB: Net earnings per share (EPS TTM)|SRx Health Solutions Inc. - Earnings per share for the trailing year|Earnings per share for the last twelve months Polyrizon Ltd|AEZS (Aeterna Zentaris) - Earnings per share for the last four quarters|Earnings per share for the last twelve months CTD Holdings (CYTH)|INZY: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Reneo Pharmaceuticals Inc. RPHM|Net earnings per share for the last four quarters COSCIENS Biopharma Inc. (CSCI)